Stock Analysis of Recursion Pharmaceuticals Inc (RXRX) - Birds Eye View

1W   2W   1M   3M   1Y   2Y   5Y   
Overview
Code RXRX
Close 8.28
Change -0.590 / 6.65 %
Volume 6509.32 K
Vol Change 3125.55 K / 92.37 %
IndustryBiotechnology
SectorHealthcare
AIO Strength Index
Technical StrengthBearish
Growth Index Low Growth Stock
Value Index Poor Value Stock
Profitability Index Poor Profitability Stock
Stability Index Low Stability Stock


Fundamental View of Recursion Pharmaceuticals Inc
PE (TTM)

-5.17

Very Poor
Price / Book

4.16

Very Poor
Price / Sales

39.99

Very Poor
Piotroski F Score

3.0

Not Good
Market Cap

1906.67 M

Enterprise Value

1519.13 M

ROA (TTM)

-56.45

Very Poor
ROE (TTM)

-80.42

Very Poor
Net Margin (TTM)

-773.10

Very Poor
Revenue

17.78 %

46928.00 K
Net Profit

22.17 %

-292562.00 K
Debt to Equity

0.0157

Excellent
Altman Z Score

3.11

Good
Quick Ratio

4.74

Very Good
Cash Ratio

4.24

Very Good


Highs/Lows of Recursion Pharmaceuticals Inc
PeriodOld priceStock ReturnS&P 500 ReturnsHighLowHigh DateLow Date
One Week9.16 9.61 % 0.513 % 9.628.2228-May-2431-May-24
Two Week9.42 12.10 % 0.486 % 9.818.2220-May-2431-May-24
One Month7.82 5.88 % 4.80 % 10.6657.7315-May-2401-May-24
Three Month13.46 38.48 % 3.56 % 13.637.13501-Mar-2419-Apr-24
Six Months6.85 20.88 % 15.54 % 15.746.527-Feb-2401-Dec-23
One year8.77 5.59 % 26.26 % 16.7454.9719-Jul-2301-Nov-23
Two year6.12 35.29 % 27.72 % 16.7454.5419-Jul-2302-May-23


Technical View of Recursion Pharmaceuticals Inc
RSI

40.88

Neutral
MACD

-0.0258

Bullish
ADX

17.54

Bearish
Super Trend

7.98

Mild Bullish
Williams %R

-97.55

Mild Bullish
CCI

-100.05

Mild Bullish


EMA 5

8.72

Strong Bearish
EMA 15

8.97

Strong Bearish
EMA 50

9.16

Bearish
EMA 100

9.35

Mild Bearish
SMA 100

10.05

Strong Bearish
SMA 200

8.90

Mild Bearish
SMA 5 / 20

8.78 / 9.12

Strong Bearish
SMA 15 / 50

9.24 / 8.86

Mild Bullish
SMA 50 / 200

8.86 / 8.90

Bearish




Charts of Recursion Pharmaceuticals Inc


Returns of Recursion Pharmaceuticals Inc with Peers
Period / StockRXRXRCKTCPRXTDOC
1 Week-9.61%-0.467%1.89%-2.09%
1 Mth5.88%-0.929%7.44%-11.84%
3 Mth-38.48%-27.24%0.873%-25.46%
6mth20.88%-8.62%12.06%-38.04%
1 Year-5.59%1.86%40.00%-51.45%
2 Year35.29%79.92%124.58%-67.03%
5 Years-30.56%362.00%-80.66%
charts-
View All Together in Chart      Inline           Tile

Compare Fundamentals of Recursion Pharmaceuticals Inc with Peers
Ratio / StockRXRXRCKTCPRXTDOC
PE-5.17-3518.5128.40-4006.26
P/B4.161902.324.61406.07
ROA-56.45-47.8413.66-5.38
ROE-80.42-54.0716.22-10.14
Debt To Equity0.01570.00550.00100.666
Revenue46928.00 K
17.78 % 		0
% 		348393 K
62.65 % 		2579.60 M
7.18 %
Net Income-292562.00 K
22.17 % 		-252658.00 K
13.88 % 		62037.00 K
25.33 % 		-4001.55 M
70.71 %


Technicals of Recursion Pharmaceuticals Inc with Peers
Technical / StockRXRXRCKTCPRXTDOC-
ADX17.5418.5219.2028.35
CMF-0.188-0.225-0.127-0.185
MFI58.7927.9855.0226.75
RSI40.8838.5553.0731.11
MACD Abv SignalFalseFalseFalseFalse
Price Above 50 MAFalseFalseTrueFalse-
Price Above 200 MAFalseFalseTrueFalse-


About : Recursion Pharmaceuticals Inc

Address : 41 South Rio Grande Street, Salt Lake City, UT, United States, 84101
Tel : 385 269 0203
URL : https://www.recursion.com
Code : RXRX, ISIN : US75629V1044, Exchange : NASDAQ, Country : USA
Fiscal Year End : December
IPO date : 16_Apr_2021
Employee Count : 500

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.


Note : All Data Generated at the End of Trading Hours (EOD Data)